## RECEIVED @ 003/005 CENTRAL FAX CENTER

JUL 0 2 2007

Our Docket No.: 102912-200

Page 1 of 3

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Lorenz Poellinger

Docket:

3743/49008

Teresa Pereira

Jorge Runs

Serial No.:

09/922,958

Art Unit:

1642

Filed:

August 7, 2001

Examiner:

Brandon J. Fetterolf

Assignee:

AngioGenetics Sweden AB

Conf. No.:

9818

Customer No.:

27267

Our Reference:

102912-200

Title:

MECHANISM OF CONDITIONAL REGULATION OF THE

HYPOXIA-INDUCIBLE FACTOR-1 BY THE VON HIPPEL-LINDAU

TUMOR SUPPRESSOR PROTEIN

## REVOCATION OF POWER OF ATTORNEY, GRANT OF NEW POWER OF ATTORNEY, AND CHANGE OF CORRESPONDENCE ADDRESS (INCLUDES STATEMENT UNDER 37 C.F.R. §3.73(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

AngioGenetics Sweden AB of Stockholm, Sweden ("Assignee"), organized under the laws of the Sweden, states that it is the current Assignee of the entire right, title, and interest to the above-identified U.S. patent application by virtue of a chain of title as follows:

	CERTIFICATE OF MAILING OR TRANSMISSION (37 CFR 1.8(a))
1 here	by certify that this correspondence (along with any paper referred to as being attached or enclosed) is being:
	deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
Ø	transmitted by faosimile on the date shown below to the United States Patent and Tradernark Office via facsimile at (571) 273-8300.
Date:	02 July 2007 Signed: Todd E. Garabedian, Ph.D.

Our Docket No.: 102912-200

Page 2 of 3

1. From: Lorenz Poellinger

Jorge Ruas Teresa Percira To: Aspera Pharmaceuticals

The document was recorded in the United States Patent and Trademark Office at

Reel: 012335, Framc: 0026.

2. From: Aspera Pharmaceuticals To: AngioGenetics Sweden AB

The document was recorded in the United States Patent and Trademark Office at

Reel: 012481, Frame: 0234.

The undersigned is empowered to sign this statement on behalf of the Assignee,

Assignee hereby revokes all previous powers of attorney or authorization of agent given in this U.S. patent application.

Assignee hereby appoints the practitioners of Wiggin and Dana LLP, who are identified by the U.S. Patent & Trademark Office under Customer Number 27267 and to transact all business in the Patent and Trademark Office connected therewith.

Please address all future written and fax correspondence to Customer Number:

\*27267\*

27267

ATENT TRADEMARK OFFICE

Patent Docket Coordinator WIGGIN and DANA LLP One Century Tower P.O. Box 1832 New Haven. CT 06508-1832 Telephone: (203) 498-4400 Facsimile: (203) 782-2889

Our Docket No.: 102912-200

Page 3 of 3

Please direct all phone and email communications to Todd E. Garabedian, Ph.D., Reg. No. 39.197 at Wiggin and Dana LLP, phone: 203-498-4400 and email: tgarabedian@wiggin.com.

Signature of authorized person for AngioGenetics Sweden AB

By: Mats Hellström

Title: Chief Executive Officer

Date: 7 June 2007

CONTACT INFORMATION: WIGGIN and DANA LLP One Century Tower New Haven, CT 06508-1832 Telephone: (860) 297-3716 Facsimile: (203) 782-2889 Email: tgarabedian@wiggin.com

\18516\6\54412.1